Hypertrophic cardiomyopathy and liver involvement were exclusively found in patients with SUCLG1 mutations, whereas epilepsy was much more frequent in patients with SUCLA2 mutations compared to patients with SUCLG1 mutations. Here, SUCLG1 is linked to hypertrophic cardiomyopathy.